IDH1 and cholangiocarcinoma: Molecular profiling efforts by multiple groups have ultimately corroborated that CCA, particularly iCCA, harbor alterations in IDH1/2, FGFR2, ERBB2, EGFR, BRAF, MET, BRCA1/2, and NTRK with viable classes of agents available for therapeutic targeting [14,15,16,17,18,19,20].